Surging Prevalence Of Cardiovascular Diseases Propels Growth In The Angina Pectoris Drug Market Is Supporting Development Across The Angina Pectoris Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Trend Is Expected For The Angina Pectoris Drugs Market From 2026 To 2030?

The angina pectoris drugs market has experienced substantial expansion in recent times. This market is projected to expand from $12.88 billion in 2025 to $13.63 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. Historically, this growth was driven by factors such as the increasing incidence of coronary heart disease, heightened public awareness of angina symptoms, the emergence of beta-blockers, improvements in hospital infrastructure, and the increasing use of calcium channel blockers.

The angina pectoris drugs market is anticipated to experience robust expansion over the coming years. It is projected to reach $17.67 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. This expansion during the forecast period is propelled by factors such as progress in precision medicine, the rise of wearable cardiac monitoring devices, an increasing need for combination therapies, greater investment in research and development for anti-ischemic agents, and the incorporation of telehealth into cardiac care. Key trends anticipated during this period encompass personalized strategies for angina management, the emergence of minimally invasive drug delivery systems, the adoption of fixed-dose combination therapies, an expanding elderly patient demographic, and advancements in telemedicine and remote cardiac monitoring.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp

What Key Growth Drivers Are Influencing The Angina Pectoris Drugs Market?

The rising occurrence of cardiovascular diseases is anticipated to boost the expansion of the angina pectoris drug market in the future. These diseases involve various conditions affecting the heart and blood vessels, such as coronary artery disease, hypertension, heart failure, and stroke. The growing incidence of cardiovascular diseases (CVD) is linked to factors like an aging demographic, unhealthy habits, and the widespread issue of obesity. Medicines for angina pectoris, including nitrates, beta-blockers, and calcium channel blockers, are vital for alleviating chest pain and discomfort resulting from inadequate blood supply to the heart, thereby improving patients’ overall well-being. For example, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the increasing prevalence of cardiovascular diseases is a key factor propelling the growth of the angina pectoris drug market.

Which Segment Groups Define The Angina Pectoris Drugs Market Landscape?

The angina pectoris drugs market covered in this report is segmented –

1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins

2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina

3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates

2) By Antiplatelet Agents: Aspirin, Clopidogrel

3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers

4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers

5) By Anti-Ischemic Agents: Ranolazine, Ivabradine

6) By Statins: Atorvastatin, Rosuvastatin

What Trends Are Impacting The Angina Pectoris Drugs Market?

Leading firms within the angina pectoris drug market are prioritizing the adoption of new technologies to maintain their market presence and effectively address the requirements of their current consumers. This includes instances like the U.S. Food and Drug Administration’s authorization of Labetalol Hydrochloride Injection for the management of angina. Additionally, Nitrostat (Nitroglycerin Sublingual Tablets) has received clearance from the United States Food and Drug Administration (FDA) for the prompt treatment or acute prophylactic use against angina pectoris. As an illustration, in March 2023, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, introduced Labetalol Hydrochloride Injection, USP, in a prefilled syringe. This product has been granted authorization by the United States Food and Drug Administration. Within hospital settings, the 10 mg/2 mL PFS formulation is employed for managing severe hypertension and reducing blood pressure.

Which Companies Are Influencing The Angina Pectoris Drugs Market?

Major companies operating in the angina pectoris drugs market are Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., GlaxoSmithKline plc, Lupin Pharmaceuticals Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Servier Laboratories, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., H. Lundbeck A/S

Access The Complete Angina Pectoris Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Which Region Has The Strongest Presence In The Angina Pectoris Drugs Market?

North America was the largest region in the angina pectoris drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Angina Pectoris Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp

Browse Through More Reports Similar to the Global Angina Pectoris Drugs Market 2026, By The Business Research Company

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Angina Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795